Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04024631 · ClinicalTrials.gov registry record · NA
Phenotyping Genetic Risk for Type 2 Diabetes
A NA study of Diabetes Mellitus, Type 2 and Genetics, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT04024631: Recruiting NA study of Diabetes Mellitus, Type 2 and Genetics, sponsored by University of Pennsylvania.
NCT04024631 is a NA study of Diabetes Mellitus, Type 2 and Genetics that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 100 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04024631, a NA study of Diabetes Mellitus, Type 2 and Genetics, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.
Primary Outcome
Glucose area under the curve after the 75g glucose beverage
Conditions Studied
Interventions
- OTHER 75g glucose beverage (Glucola, Trutol, or similar brand)
- OTHER DXA, whole body
Study Locations (2)
Pennsylvania
- Childrens Hospital of Philadelphia - Philadelphia
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT04024631 shows while recruiting
NCT04024631 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which 75g glucose beverage (Glucola, Trutol, or similar brand) is the first listed.
NCT04024631 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04024631 about?
NCT04024631 is a clinical study titled "Phenotyping Genetic Risk for Type 2 Diabetes". This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.
What is the current status of trial NCT04024631?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2019-06-17. Estimated completion is 2026-06-30.
What conditions does trial NCT04024631 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Genetics.
What interventions are being tested in trial NCT04024631?
The interventions under investigation include: 75g glucose beverage (Glucola, Trutol, or similar brand) (OTHER), DXA, whole body (OTHER).
Who is sponsoring clinical trial NCT04024631?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04024631 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04024631's enrollment target sits among peer trials
100 201st of 348 higher than 142 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
-
Efficacy of Using Mobile Health Applications for Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI